title: Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia.
abstract: Congenital Neutropenia (CN) is a heterogeneous bone marrow failure syndrome characterized by a maturation arrest of myelopoiesis at the level of the promyelocyte/myelocyte stage with peripheral blood absolute neutrophil counts below 0.5 x 10(9)/l. There are two major subtypes of CN as judged by inheritance: an autosomal dominant subtype, e.g. defined by neutrophil elastase mutations (approximately 60% of patients) and an autosomal recessive subtype (approximately 30% of patients), both presenting with the same clinical and morphological phenotype. Different mutations have been described (e.g. HAX1, p14 etc) in autosomal recessive CN, with HAX1 mutations in the majority of these patients. CN in common is considered as a preleukemic syndrome, since the cumulative incidence for leukemia is more than 25% after 20 years of observation. Leukemias occur in both, the autosomal dominant and recessive subtypes of CN. The individual risk for each genetic subtype needs to be further evaluated. Numbers of patients tested for the underlying genetic defect are still limited. Acquired G-CSFR (CSF3R) mutations are detected in approximately 80% of CN patients who developed acute myeloid leukemia independent of the ELA2 or HAX1 genetic subtype, suggesting that these mutations are involved in leukemogenesis. As the majority of patients benefit from G-CSF administration, HSCT should be restricted to non-responders and patients with leukaemic transformation.
authors.affiliation: Department of Paediatric Haematology/Oncology, Medical University Hannover, Hannover, Germany.
authors.forename: Cornelia
authors.initials: C
authors.lastname: Zeidler
authors.forename: Manuela
authors.initials: M
authors.lastname: Germeshausen
authors.forename: Christoph
authors.initials: C
authors.lastname: Klein
authors.forename: Karl
authors.initials: K
authors.lastname: Welte
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D002648:Child; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000209:etiology; D009154:Mutation; D009503:Neutropenia / Q000151:congenital / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy; D011506:Proteins / Q000235:genetics*; D016188:Receptors, Granulocyte Colony-Stimulating Factor / Q000235:genetics*; D011994:Recombinant Proteins; D012697:Serine Endopeptidases / Q000235:genetics*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C104759:HAX1 protein, human; D011506:Proteins; D016188:Receptors, Granulocyte Colony-Stimulating Factor; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D012697:Serine Endopeptidases; C117309:pancreatic elastase II